Lovastatin maintains nitric oxide-but not EDHF-mediated endothelium- dependent relaxation in the hypercholesterolemic rabbit carotid artery

Atherosclerosis

Volumn 142, Issue 1, 1999, Pages 97-104

  Brandes, Ralf P ^a   Behra, Andreas ^a   Lebherz, Corinna ^a   Böger, Rainer H ^a   Bode Böger, Stefanie M ^a   Mügge, Andreas ^a  

^a HANNOVER MEDICAL SCHOOL   (Germany)

Author keywords

Carotid artery; Endothelial derived hyperpolarising factor; Hypercholesterolemia; Lovastatin; Nitric oxide

Indexed keywords

ACETYLCHOLINE; CHARYBDOTOXIN; CHOLESTEROL; ENDOTHELIUM DERIVED HYPERPOLARIZING FACTOR; INDOMETACIN; MEVINOLIN; N(G) NITROARGININE; NITRIC OXIDE; POTASSIUM CHLORIDE; TETRABUTYLAMMONIUM;

ANIMAL CELL; ANIMAL TISSUE; ARTERY DILATATION; ARTICLE; CAROTID ARTERY; CONTROLLED STUDY; DRUG MECHANISM; HYPERCHOLESTEROLEMIA; MALE; NONHUMAN; PRIORITY JOURNAL; RABBIT; VASCULAR ENDOTHELIUM;

ACETYLCHOLINE; ANIMALS; ANTICHOLESTEREMIC AGENTS; BIOLOGICAL FACTORS; CAROTID ARTERIES; CHOLESTEROL; ENZYME INHIBITORS; HYPERCHOLESTEROLEMIA; LOVASTATIN; MALE; NITRIC OXIDE; NITROARGININE; RABBITS; VASODILATION; VASODILATOR AGENTS;

EID: 0032889907     PISSN: 00219150     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0021-9150(98)00197-X     Document Type: Article

References (44)

1. Bassenge E. Control of coronary blood flow by autacoids. Basic. Res. Cardiol. 90:1995;125-141.
2. Cohen R.A., Vanhoutte P.M. Endothelium-dependent hyperpolarization - beyond nitric oxide and cyclic GMP. Circulation. 92:1995;3337-3349.
3. Mombouli J.V., Vanhoutte P.M. Endothelium-derived hyperpolarizing factor(s): updating the unknown. Trends. Pharmacol. Sci. 18:1997;252-257.
4. Hecker M., Bara A.T., Bauersachs J., Busse R. Characterization of endothelium-derived hyperpolarizing factor as a cytochrome p450-derived arachidonic acid metabolite in mammals. J. Physiol. (Lond). 481:1994;407-414.
5. Campbell W.B., Gebremedhin D., Pratt P.F., Harder D.R. Identification of epoxyeicosatrienoic acids as endothelium-derived hyperpolarizing factors. Circ. Res. 78:1996;415-423.
6. Taylor S.G., Weston A.H. Endothelium-derived hyperpolarizing factor: a new endogenous inhibitor from the vascular endothelium. Trends. Pharmacol. Sci. 9:1988;272-274.
7. Chappell S.P., Lewis M.J., Henderson A.H. Effect of lipid feeding on endothelium dependent relaxation in rabbit aortic preparations. Cardiovasc. Res. 21:1987;34-38.
8. Verbeuren T.J., Jordaens F.H., VanHove C.E., VanHoydonck A.E., Herman A.G. Release and vascular activity of endothelium-derived relaxing factor in atherosclerotic rabbit aorta. Eur. J. Pharmacol. 191:1990;173-184.
9. Ludmer P.L., Selwyn A.P., Shook T.L., Wayne R.R., Mudge G.H., Alexander R.W. et al. Paradoxical vasoconstriction induced by acetylcholine in atherosclerotic coronary arteries. N. Engl. J. Med. 315:1986;1046-1051.
10. Mügge A., Brandes R.P., Böger H., Dwenger A., Bode-Böger S., Kienke S. et al. The vascular release of superoxide radicals is enhanced in hypercholesterolemic rabbits. J. Cardiovasc. Pharmacol. 24:1994;994-998.
11. Ohara Y., Peterson T.E., Harrison D.G. Hypercholesterolemia increases endothelial superoxide anion production. J. Clin. Invest. 91:1993;2546-2551.
12. Najibi S., Cowan C.L., Palacino J.J., Cohen R.A. Enhanced role of potassium channels in relaxations to acetylcholine in hypercholesterolemic rabbit carotid artery. Am. J. Physiol. 266:1994;H2061-H2067.
13. Gnitro-L-arginine- and indomethacin-resistant endothelium-dependent relaxation in the rabbit renal artery: effect of hypercholesterolemia. Atheriosclerosis. 135:1997;49-55.
14. Anderson T.J., Meredith I.T., Yeung A.C., Frei B., Selwyn A.P., Ganz P. The effect of cholesterol-lowering and antioxidant therapy on endothelium-dependent coronary vasomotion. N. Engl. J. Med. 332:1995;488-493.
15. Treasure C.B., Klein J.L., Weintraub W.S., Talley J.D., Stillabower M.E., Kosinski A.S. et al. Beneficial effects of cholesterol-lowering therapy on the coronary endothelium in patients with coronary artery disease. N. Engl. J. Med. 332:1995;481-487.
16. Ohara Y., Peterson T.E., Sayegh H.S., Subramanian R.R., Wilcox J.N., Harrison D.G. Dietary correction of hypercholesterolemia in the rabbit normalises endothelial superoxide anionen production. Circulation. 92:1995;889-903.
17. Böger R.H., Bode-Böger S.M., Mügge A., Kienke S., Brandes R., Dwenger A., Frölich J.C. Supplementation of hypercholesterolemic rabbits with L-arginine reduces the vascular release of superoxide anions and restores NO production. Atherosclerosis. 117:1995;273-284.
18. Förstermann U., Mügge A., Alheid U., Haverich A., Frölich J.C. Selective attenuation of endothelium-mediated vasodilation in atherosclerotic human coronary arteries. Circ. Res. 62:1988;185-190.
19. Nagao T., Vanhoutte P.M. Characterisation of endothelium-dependent relaxations resistant to nitro-L-arginine in the porcine coronary artery. Br. J. Pharmacol. 107:1992;1102-1107.
20. Garcia M.L., Knaus H.G., Munojos P., Slaughter R.S., Kaczorowski G.J. Charybdotoxin and its effects on potassium channels. Am. J. Physiol. 269:1995;C1-C10.
21. G-nitro arginine (L-NOARG), a novel, L-arginine-reversible inhibitor of endothelium-dependent vasodilatation in vitro. Br. J. Pharmacol. 99:1990;408-412.
22. Mügge A., Peterson T., Harrison D.G. Release of nitrogen oxides from cultured bovine aortic endothelial cells is not impaired by calcium channel antagonists. Circulation. 83:1991;1404-1409.
23. Garthwaite J., Southam E., Boulton C.L., Nielsen E.B., Schmidt K., Mayer B. Potent and selective inhibition of nitric oxide-sensitive guanylyl cyclase by 1H-[1,2,4]oxadiazolo[4,3-a]quinoxalin-1-one. Mol. Pharmacol. 48:1995;184-188.
24. Busse R., Fleming I. Endothelial dysfunction in atherosclerosis. J. Vasc. Res. 33:1996;181-194.
25. Kitagawa S., Yamaguchi Y., Kunitomo M., Sameshima E., Fujiwara M. Ng-nitro-L-arginine-resistant endothelium-dependent relaxation induced by acetylcholine in the rabbit renal artery. Life. Science. 55:1994;491-498.
26. Dong H., Waldron G.J., Galipeau D., Cole W.C., Triggle C.R. NO/PGI2-independent vasorelaxation and the cytochrome P450 pathway in rabbit carotid artery. Br. J. Pharmacol. 120:1997;695-701.
27. Lamontagne D., König A., Bassenge E., Busse R. Prostacyclin and Nitric oxide contribute to the vasodilator action of acetylcholine and bradykinin in the intact rabbit coronary bed. J. Cardiovasc. Pharmacol. 20:1992;652-657.
28. Najibi S., Cohen R.A. Enhanced role of K+ channels in relaxations of hypercholesterolemic rabbit carotid artery to NO. Am. J. Physiol. 269:1995;H805-H811.
29. Bauersachs J., Popp R., Hecker M., Sauer E., Fleming I., Busse R. Nitric oxide attenuates the release of endothelium-derived hyperpolarizing factor. Circulation. 94:1996;3341-3347.
30. Kristof A.S., Noorhosseini H., Hussain S.N. Attenuation of the endothelium-dependent hyperpolarizing factor by bacterial lipopolysaccharides. Eur. J. Pharmacol. 328:1997;69-73.
31. Zygmunt P.M., Högestätt E.D. Role of potassium channels in endothelium-dependent relaxation resistant to nitroarginine in the rat hepatic artery. Br. J. Pharmacol. 117:1996;160-1606.
32. Walters D., Higginson W.D., Gladstone P., Kimball B., LeMay M., Boccuzzi S.J., Lesperance J. Effects of monotherapy with an HMG-CoA reductase inhibitor on the progression of coronary atherosclerosis as assessed by serial quantitative arteriography. The Canadian coronary atherosclerosis intervention trial. Circulation. 89:1994;959-968.
33. Blankenhorn D.H., Azen S.P., Kramsch D.M., Mack W.J., Cashin-Hemphill L., Hodis H.N. et al. Coronary angiographic changes with lovastatin therapy. The monitored atherosclerosis regression study (MARS). Annals. Internal. Med. 119:1993;969-976.
34. Senaratne M.P., Thomson A.B., Kappagoda C.T. Lovastatin prevents the impairment of endothelium dependent relaxation and inhibits accumulation of cholesterol in the aorta in experimental atherosclerosis in rabbits. Cardiovasc. Res. 25:1991;568-578.
35. Corsini A., Bernini F., Quarato P., Donetti E., Bellosta S., Fumagalli R. et al. Non-lipid-related effects of 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors. Cardiology. 87:1996;458-468.
36. Munro E., Patel M., Chan P., Betteridge L., Clunn G., Gallagher K. et al. Inhibition of human vascular smooth muscle cell proliferation by lovastatin: the role of isoprenoid intermediates of cholesterol synthesis. Eur. J. Clin. Invest. 24:1994;766-772.
37. Somar M.R., Donetti E., Parolini C., Mazzini G., Ferrari C., Fumagalli R. et al. HMG-CoA reductase inhibitors. In vivo effects on carotid intimal thickening in normocholesterolemic rabbits. Arterioscler. Thromb. 13:1993;571-578.
38. Kobashigawa J.A., Katznelson S., Laks H., Johnson J.A., Yeatman L., Wang X.M. et al. Effect of pravastatin on outcomes after cardiac transplantation. N. Engl. J. Med. 333:1995;621-627.
39. Zeiher A.M., Drexler H., Wollschläger H., Just H.J. Modulation of coronary vasomotor tone in humans. Progressive endothelial dysfunction with different early stages of coronary atherosclerosis. Circulation. 83:1991;391-401.
40. Böger R.H., Bode-Böger S.M., Brandes R.P., Phivthong-ngam L., Böhme M., Nafe R. et al. Dietary L-arginine reduces the progression, but does not induce regression of atherosclerosis in cholesterol-fed rabbits-comparison with lovastatin. Circulation. 96:1997;1282-1290.
41. Pfister S.L., Falck J.R., Cambell W.B. Enhanced synthesis of epoxyeicosatrienoic acids by cholesterol-fed rabbit aorta. Am. J. Physiol. 261:1991;H843-H852.
42. Shin W.S., Sasaki T., Toyo-oka T. Autocrine and paracrine effects of endothel-derived relaxing factor on intracellular Ca2+ of endothelial cells and vascular smooth muscle cells. J. Biol. Chem. 267:1992;20377-20382.
43. Khatsenko O.G., Gross S.S., Rifkind A.B., Vane J.R. Nitric oxide is a mediator of the decrease in cytochrome P450-dependent metabolism caused by immunostimulants. Proc. Natl. Acad. Sci. USA. 90:1993;11147-11151.
44. Khatsenko O., Kikkawa Y. Nitric oxide differentially affects constitutive cytochrome P450 isoforms in rat liver. J. Pharmacol. Exp. Ther. 280:1997;1463-1470.